US Patent 11,286,486: What the Claims Actually Cover, and Where the Landscape Is Crowded
United States Patent 11,286,486 claims method-of-treatment coverage for TTR-associated diseases using a double-stranded RNAi agent with tightly defined sequence identity constraints, specific chemically modified nucleotides, and optional GalNAc targeting ligands. The patent’s enforceable scope is primarily constrained by (i) the sense and antisense strand identity (SEQ ID NO: 10 and SEQ ID NO: 7) and (ii) the chemical modification pattern (2′-OMe, 2′-fluoro, phosphorothioate linkage) plus optional ligand identity and attachment.
What is claimed? (High-level claim architecture)
The claims are centered on a method:
- Treat a subject with a TTR-associated disease
- Administer a therapeutically effective amount of a double-stranded RNAi agent
- RNAi agent has:
- Sense strand and antisense strand with ≤4 / ≤3 / ≤2 / ≤1 modified nucleotide mismatches relative to defined reference sequences (SEQ ID NO: 10 and SEQ ID NO: 7)
- Nucleotide chemistry restricted to:
- 2′-O-methyl (2′-OMe) for A, C, G, U positions labeled as a, c, g, u
- 2′-fluoro substitutions for positions labeled as Af, Cf, Gf, Uf
- phosphorothioate linkage at s
- Optional ligand conjugation (claims 14–20, and then species/labeled specifics in claim 21)
- Administration route includes broad categories, with narrower fallbacks around subcutaneous and self-administration.
Claim 1: the independent “anchor” for infringement risk
Claim 1 is the broadest independent method claim and defines the core inventive concept:
Treating a subject suffering from a TTR-associated disease by administering a therapeutically effective amount of a double stranded RNAi agent where:
- Sense strand differs by no more than 4 modified nucleotides from:
- 5′-usgsggauUfuCfAfUfguaaccaaga-3′ (SEQ ID NO: 10)
- Antisense strand differs by no more than 4 modified nucleotides from:
- 5′-usCfsuugGfuuAfcaugAfaAfucccasusc-3′ (SEQ ID NO: 7)
- Chemistry:
- a, c, g, u are 2′-OMe
- Af, Cf, Gf, Uf are 2′-fluoro
- s is a phosphorothioate linkage
This claim is a classic “defined siRNA scaffold + limited variant tolerance” approach. It is designed to capture minor sequence changes that remain within the defined “≤4 modified nucleotide” mismatch envelope.
How tight are the sequence constraints? (Identity vs “modified nucleotide” mismatch)
The claims are explicit that the tolerance is measured as “differing by no more than N modified nucleotides” rather than total nucleotide difference. Practically, this matters because an infringing product can vary in unmodified positions, but still be captured if it stays within the modified-position mismatch tolerance.
Tolerance ladder (claims 9–11)
- Claim 9: ≤3 modified nucleotide differences on both sense and antisense strands
- Claim 10: ≤2 modified nucleotide differences
- Claim 11: ≤1 modified nucleotide differences
Each is relative to the same SEQ ID references (sense SEQ ID NO: 10; antisense SEQ ID NO: 7).
“Consists of” backstop (claims 12–13)
- Claim 12: sense comprises SEQ ID NO: 10 exactly; antisense comprises SEQ ID NO: 7 exactly
- Claim 13: sense consists of SEQ ID NO: 10 exactly; antisense consists of SEQ ID NO: 7 exactly
This narrows capture to fully exact strands (no extra components in the strand sequence definition).
Business implication: the patent does not rely only on “exact strand identity.” It also claims a defined zone of permissible modification-position divergence. In portfolio and freedom-to-operate (FTO) work, you treat any competing RNAi construct as high risk if it uses the same two-strand design with minor departures limited to ≤4 modified-position differences.
What chemical modifications are locked in?
Modification types and symbols in the claim
Across claim 1 and the dependents:
- 2′-O-methyl (2′-OMe) at labeled positions:
- a, c, g, u → 2′-OMe A, C, G, U
- 2′-fluoro at labeled positions:
- Af, Cf, Gf, Uf → 2′-fluoro A, C, G, U
- phosphorothioate linkage:
- s is a phosphorothioate linkage
The claim text makes these chemistry requirements structural conditions for infringement. A competing RNAi chemistry that deviates from this pattern can fall outside the independent claim if the deviation is not captured by the claim’s definition.
Which diseases are included? (Named TTR indications list)
The claims include both generic and enumerated coverage.
Disease list (claims 3 and 23)
- Senile systemic amyloidosis (SSA)
- Systemic familial amyloidosis
- Familial amyloidotic polyneuropathy (FAP)
- Familial amyloidotic cardiomyopathy (FAC)
- Leptomeningeal/Central Nervous System (CNS) amyloidosis
- Hyperthyroxinemia
Mutation framing (claims 2 and 22)
- Claims add coverage when the subject carries a TTR gene mutation associated with disease.
Business implication: even if a product targets one TTR phenotype, the claim language does not limit to a single TTR disorder, which can broaden exposure if any intended use falls within the enumerated list.
Administration route and delivery constraints
Broad route list (claims 4 and 24)
Administered by a means selected from:
- subcutaneous, intravenous, intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic, cerebrospinal
- or any combinations
Narrowing dependent claims
- Claim 5: subcutaneous administration
- Claim 6: self-administration
- Claim 7: self-administration via pre-filled syringe or auto-injector syringe
- Claim 8: chronically administered
- Parallel narrowing in human-specific claim set (claims 25–28)
Business implication: the broad route list supports enforcement across multiple delivery formats, while dependent claims create added leverage for SC chronic self-administered regimens, which are typical of GalNAc-targeted dosing strategies.
Ligand-targeting scope: what is actually claimed beyond “sequence + chemistry”?
General ligand coverage (claims 14–15)
- Claim 14: dsRNAi agent further comprises at least one ligand
- Claim 15: sense strand conjugated to at least one ligand
This creates an additional dimension of coverage: you cannot avoid infringement solely by keeping the same RNAi sequence/chemistry if you also fall into the ligand-conjugated variants covered by the additional dependents.
Specific ligand identity (claim 16)
- Ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker
Attachment location (claims 18–20)
- Claim 18: attached to the 3′ end of the sense strand
- Claim 19: conjugated as shown in the schematic (X is O or S)
- Claim 20: X is O
Specific human-labeled ligand structure (claim 21)
Claim 21 includes a defined ligand moiety labeled L96:
- L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol
Business implication: the ligand portion is not generic “any targeting ligand.” It is tied to GalNAc derivatives plus a specific attachment geometry (branched linker, 3′ end attachment, and in one dependent claim the oxygen vs sulfur linkage). If a competitor uses non-GalNAc targeting or a different linker architecture, it can attempt to move outside these dependent claim hooks.
Human-method claim set: how claim 21 changes the scope
Claim 21 is another independent method claim, but with a specific ligand structure included in the agent definition:
- “double stranded ribonucleic acid (RNAi) agent”
- sense sequence and antisense sequence are explicitly given and the modifications and phosphorothioate linkage are specified
- adds L96 as the ligand
The result is two-layer coverage:
- A sequence/chemistry-first method (claim 1 and variants)
- A sequence/chemistry plus a specific GalNAc ligand structure method (claim 21 and variants)
Dependent human claims (22–28) mirror claims 2–8: mutation presence, disease list, broad route list, then subcutaneous, self-administration, and chronic dosing.
What does the claim set suggest about the product/technology targeted?
The combination of:
- tight dsRNA identity tolerances
- 2′-OMe and 2′-fluoro patterns
- phosphorothioate linkages
- GalNAc targeting on the sense strand at the 3′ end
maps to a common siRNA design strategy aimed at liver TTR reduction with GalNAc-mediated hepatocyte uptake. The patent is drafted to claim both:
- generic dosing methods across TTR indications
- specific chemical-ligand incarnations that are likely to correspond to a commercial RNAi therapeutic candidate.
Patent landscape implications (scope boundaries and blocking positions)
1) High-risk design space for competitors
A competing RNAi molecule or combination enters the highest exposure zone if it matches all of the following:
- Uses the same sense and antisense reference sequences (SEQ ID NO: 10 and SEQ ID NO: 7)
- Deviates only within ≤4 modified nucleotide mismatches (and potentially even less for narrower dependent claims)
- Uses the same modification types: 2′-OMe at a/c/g/u positions and 2′-fluoro at Af/Cf/Gf/Uf positions, with phosphorothioate linkage at s
- Treats any named TTR-associated disease (or claims to treat mutation-driven TTR disease broadly)
- Administers by routes that include SC and other listed administration routes
- Uses GalNAc-conjugated targeting with the claimed linker architecture (for dependents)
2) Key “escape routes” that reduce alignment with the claim language
Based on claim text alone, the main legal escape levers are:
- Changing the dsRNA design so that modified nucleotides differ by more than N thresholds from the defined SEQ ID scaffolds
- Altering the chemical modification pattern so that 2′-OMe/2′-fluoro/phosphorothioate constraints are not met in the claimed manner
- Avoiding GalNAc targeting with the specified linker and attachment conditions (to avoid dependents 14–20 and 21’s L96-specific ligand embodiment)
3) Landscape structure: method claims dominate
This patent is a method-of-treatment claim set. That matters for enforcement strategy:
- It pushes the burden of proof toward use-based infringement, tied to how the therapy is administered and for what condition.
- It can support enforcement through labeling and clinical use even when manufacturing details are less accessible, as long as the claimed agent structure and use are established.
Claim-by-claim risk map (condensed)
| Claim |
What it adds beyond Claim 1 |
Practical infringement trigger |
| 1 |
Core dsRNA sense/antisense with ≤4 modified nucleotide mismatch; exact chemistry types |
Any therapy that matches sequence+chemistry within ≤4 modified-position divergence and treats a TTR-associated disease |
| 2 |
Subject carries mutation |
Expanded coverage when prescribing for genetically defined TTR disease |
| 3 |
Named TTR indication list |
Coverage anchored to SSA, FAP, FAC, CNS amyloidosis, hyperthyroxinemia, etc. |
| 4 |
Broad administration routes |
Route varies but still within list |
| 5 |
SC route |
Higher relevance to SC dosing products |
| 6 |
Self-administration |
Home-use systems increase relevance |
| 7 |
Prefilled syringe or auto-injector |
Directly tied to device format |
| 8 |
Chronic dosing |
Fits label-like chronic treatment paradigms |
| 9–11 |
Tighter mismatch tolerances (≤3, ≤2, ≤1) |
Strengthens coverage for near-exact variants |
| 12–13 |
“comprises” vs “consists” exact sequences |
Captures fully exact strand embodiments |
| 14–15 |
Adds ligand requirement and conjugation to sense strand |
Must also meet ligand-related features |
| 16 |
GalNAc derivatives with bivalent/trivalent branched linker |
Limits ligand scope |
| 18–20 |
3′ attachment; schematic link with X=O |
Narrows to specific attachment chemistry geometry |
| 21 |
L96 defined GalNAc ligand + explicit dsRNA sequences |
Captures a specific “human” embodiment with defined ligand structure |
| 22–28 |
Mirrored mutation/disease/route/self-admin/chronic coverage in human claim set |
Aligns with labeled human therapeutic use cases |
Key Takeaways
- Core claim scope (Claim 1) is a method to treat TTR-associated diseases using a dsRNAi agent that matches SEQ ID NO: 10 (sense) and SEQ ID NO: 7 (antisense) with ≤4 modified nucleotide mismatch tolerance and defined 2′-OMe / 2′-fluoro / phosphorothioate chemistry.
- Enforceable variants are layered through tighter mismatch dependents (≤3, ≤2, ≤1) and exact “consists of” strand language.
- Delivery and patient-use scope includes a broad route list but adds extra coverage for subcutaneous, self-administration, prefilled syringe/auto-injector, and chronic dosing.
- Ligand-targeting dependents introduce GalNAc-specific scope: GalNAc derivatives on the sense strand at the 3′ end via branched linker constructs, including a specific ligand structure L96 in the human independent claim (claim 21).
- The patent landscape risk concentrates on therapies that keep the same RNAi scaffold and modification pattern, and that use GalNAc targeting consistent with the claimed attachment and linker architecture.
FAQs
-
Does the patent claim exact siRNA sequences only?
No. Claim 1 covers variants with up to ≤4 modified nucleotide differences from the reference sequences, with additional dependent claims narrowing to ≤3, ≤2, ≤1 and then exact “comprises/consists” embodiments.
-
Are the nucleotide modifications required for infringement?
Yes. The claims require 2′-O-methyl at labeled positions, 2′-fluoro at labeled positions, and phosphorothioate linkages at labeled positions.
-
Is GalNAc targeting required?
Not for Claim 1. Ligand concepts appear in dependents (claims 14–20). Claim 21 includes a specific L96 GalNAc ligand embodiment.
-
What administration routes are covered?
A broad list including subcutaneous, intravenous, intramuscular, and other routes is included, with additional dependent claims focused on subcutaneous self-administration via prefilled syringes or auto-injectors.
-
Which TTR diseases are explicitly included?
The claims list SSA, systemic familial amyloidosis, FAP, FAC, leptomeningeal/CNS amyloidosis, and hyperthyroxinemia.
References (APA)
[1] United States Patent 11,286,486. Method of treating TTR-associated disease using double-stranded RNAi agent. (Claim text as provided by user).
